JP2019533675A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533675A5
JP2019533675A5 JP2019520024A JP2019520024A JP2019533675A5 JP 2019533675 A5 JP2019533675 A5 JP 2019533675A5 JP 2019520024 A JP2019520024 A JP 2019520024A JP 2019520024 A JP2019520024 A JP 2019520024A JP 2019533675 A5 JP2019533675 A5 JP 2019533675A5
Authority
JP
Japan
Prior art keywords
domain
antibody molecule
tetravalent antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019520024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533675A (ja
JP7269167B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/056814 external-priority patent/WO2018071913A2/en
Publication of JP2019533675A publication Critical patent/JP2019533675A/ja
Publication of JP2019533675A5 publication Critical patent/JP2019533675A5/ja
Priority to JP2023069848A priority Critical patent/JP7796079B2/ja
Application granted granted Critical
Publication of JP7269167B2 publication Critical patent/JP7269167B2/ja
Priority to JP2025119440A priority patent/JP2025142045A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019520024A 2016-10-14 2017-10-16 モジュラー四価二重特異性抗体プラットフォーム Active JP7269167B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023069848A JP7796079B2 (ja) 2016-10-14 2023-04-21 モジュラー四価二重特異性抗体プラットフォーム
JP2025119440A JP2025142045A (ja) 2016-10-14 2025-07-16 モジュラー四価二重特異性抗体プラットフォーム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408271P 2016-10-14 2016-10-14
US62/408,271 2016-10-14
PCT/US2017/056814 WO2018071913A2 (en) 2016-10-14 2017-10-16 Modular tetrameric bispecific antibody platform

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023069848A Division JP7796079B2 (ja) 2016-10-14 2023-04-21 モジュラー四価二重特異性抗体プラットフォーム

Publications (3)

Publication Number Publication Date
JP2019533675A JP2019533675A (ja) 2019-11-21
JP2019533675A5 true JP2019533675A5 (cg-RX-API-DMAC10.html) 2020-11-26
JP7269167B2 JP7269167B2 (ja) 2023-05-08

Family

ID=60327374

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019520024A Active JP7269167B2 (ja) 2016-10-14 2017-10-16 モジュラー四価二重特異性抗体プラットフォーム
JP2023069848A Active JP7796079B2 (ja) 2016-10-14 2023-04-21 モジュラー四価二重特異性抗体プラットフォーム
JP2025119440A Pending JP2025142045A (ja) 2016-10-14 2025-07-16 モジュラー四価二重特異性抗体プラットフォーム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023069848A Active JP7796079B2 (ja) 2016-10-14 2023-04-21 モジュラー四価二重特異性抗体プラットフォーム
JP2025119440A Pending JP2025142045A (ja) 2016-10-14 2025-07-16 モジュラー四価二重特異性抗体プラットフォーム

Country Status (7)

Country Link
US (2) US20200017588A1 (cg-RX-API-DMAC10.html)
EP (1) EP3526257A2 (cg-RX-API-DMAC10.html)
JP (3) JP7269167B2 (cg-RX-API-DMAC10.html)
CN (2) CN110214152B (cg-RX-API-DMAC10.html)
AU (2) AU2017341936B2 (cg-RX-API-DMAC10.html)
CA (1) CA3038504A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018071913A2 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031194A1 (en) * 2016-07-22 2018-01-25 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
EP3526257A2 (en) * 2016-10-14 2019-08-21 Dana-Farber Cancer Institute, Inc. Modular tetravalent bispecific antibody platform
WO2018145075A1 (en) * 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
EP3880247A4 (en) * 2018-11-13 2022-10-26 JN Biosciences, LLC Bispecific antibodies for activation of immune cells
JP2022510218A (ja) * 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
CA3159308A1 (en) * 2019-12-02 2021-06-10 Wayne A. Marasco Antibodies against pd-l1 and methods of use thereof
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业(上海)股份有限公司 四价双特异性抗体、其制备方法和用途
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业(上海)股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
WO2023034288A1 (en) 2021-08-31 2023-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
WO2023097024A1 (en) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
AU2023232045A1 (en) 2022-03-09 2024-09-26 Dana-Farber Cancer Institute, Inc. Genetically engineered b cells and methods of use thereof
CA3263665A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anti-CLDN4 antibodies and their methods of use
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
CN121399164A (zh) * 2023-06-20 2026-01-23 戴纳立制药公司 双重转运体及使用方法
WO2026117666A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Bispecific antibodies for treating cancer
WO2026117664A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Engineered cells and uses thereof for treating cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO2003002144A1 (en) * 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN1914226B (zh) 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
EP1695093A1 (en) * 2003-12-05 2006-08-30 multimmune GmbH Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
EP1979379B1 (en) 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
JP2011524966A (ja) * 2008-02-22 2011-09-08 ダウ グローバル テクノロジーズ エルエルシー 熱エネルギー貯蔵材料
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
EP3957653A1 (en) 2010-06-02 2022-02-23 Dana Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
CN103906533A (zh) * 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
EP2794662A1 (en) * 2011-12-22 2014-10-29 F.Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
US8961971B2 (en) 2011-12-22 2015-02-24 Development Center For Biotechnology Bispecific T-cell activator antibody
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
EP2850106B1 (en) * 2012-05-18 2022-03-23 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EP2920210B1 (en) * 2012-11-19 2017-08-30 Baliopharm AG Recombinant bispecific antibody binding to cd20 and cd95
CN105530959B (zh) 2013-03-15 2021-09-17 纪念斯隆-凯特琳癌症中心 多聚化技术
EP4292657A3 (en) 2013-03-15 2024-03-20 Dana Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
KR20160122127A (ko) * 2013-12-23 2016-10-21 자임워크스 인코포레이티드 C-말단의 경쇄 폴리펩타이드 연장부를 포함하는 항체 및 이의 컨쥬게이트 및 이들의 사용방법
EP3119804A2 (en) 2014-03-19 2017-01-25 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
WO2015164865A1 (en) 2014-04-25 2015-10-29 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
PL3151921T3 (pl) * 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
CA2962949C (en) 2014-10-06 2024-03-05 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
US11135282B2 (en) 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
EP3526257A2 (en) * 2016-10-14 2019-08-21 Dana-Farber Cancer Institute, Inc. Modular tetravalent bispecific antibody platform
JP7649239B2 (ja) * 2018-11-30 2025-03-19 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド キメラ抗原受容体ファクトリおよびその使用方法

Similar Documents

Publication Publication Date Title
JP2025142045A5 (cg-RX-API-DMAC10.html)
JP2023518134A5 (cg-RX-API-DMAC10.html)
Holliger et al. Engineered antibody fragments and the rise of single domains
JP2020530989A5 (cg-RX-API-DMAC10.html)
JP7590034B2 (ja) Nkg2aを標的にする抗体及びその使用
JP7575100B2 (ja) 免疫細胞活性化のための二重特異性抗体
JP2024532485A5 (cg-RX-API-DMAC10.html)
JP2023505318A5 (cg-RX-API-DMAC10.html)
JP2024023228A5 (cg-RX-API-DMAC10.html)
JP2019514361A5 (cg-RX-API-DMAC10.html)
FI3334765T3 (fi) Yksidomeenivasta-aineisiin perustuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
CA3146019A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
RU2019105693A (ru) Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага
IL262321B2 (en) Compositions and methods for selective protein expression
JP2024511423A5 (cg-RX-API-DMAC10.html)
JP2019523630A5 (cg-RX-API-DMAC10.html)
JP2018525033A5 (cg-RX-API-DMAC10.html)
JP2017529067A (ja) Cd3結合ドメイン
JP2019512207A5 (cg-RX-API-DMAC10.html)
JP2022523710A5 (cg-RX-API-DMAC10.html)
JP2024504162A5 (cg-RX-API-DMAC10.html)
CN115066274A (zh) 三价结合分子
CN115667317A (zh) 全人源的靶向cd19和cd22双特异抗原嵌合受体及其应用
JP2021513857A5 (cg-RX-API-DMAC10.html)
JP2023514232A5 (cg-RX-API-DMAC10.html)